Arbutus Biopharma just crossed a threshold most small-cap clinical-stage biotechs never reach: it holds roughly $460M of pro-forma cash and marketable securities after the $178.7M Moderna settlement payment arrived on July 8, 2026, against a market capitalization of only $922.5M at the August 11, 2026 close of $4.67. The market is treating the windfall as transitory noise even though management has committed to returning up to $230M of capital through repurchases and to receiving an additional dividend from its 16% Genevant stake in Q3 2026. Underneath the legal headlines, the operating story has narrowed to two HBV assets (imdusiran in Phase 2a follow-up and AB-101 in Phase 1a/1b) running on $10M of quarterly opex, with the company explicitly burning only $8.1M of cash in Q1 2026 versus $13.4M a year earlier. The Q1 2026 print of $179.1M in revenue and $169.7M of GAAP net income is almost entirely the Moderna settlement accrual, but the $2.5B+ in cumulative LNP litigation upside (Pfizer/BioNTech U.S. trial, three new international actions, plus a contingent $1.3B Moderna §1498 appeal payment) reframes the equity as a litigation asset with a free cHBV option. The single load-bearing risk is whether Pfizer/BioNTech settles like Moderna did, and the falsifiable clock is the next U.S. District Court scheduling order in the New Jersey matter, which the September 2025 claim construction ruling has positioned in Arbutus's favor.